ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive gastric cancer.
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
Adding Tykerb to chemotherapy in HER-2 positive gastric cancer patients was proven safe in a phase 2 trial
Novel HER2 Conjugate Promising as Salvage for Solid Tumors
A small trial of a new antibody-drug conjugate that targets HER2 produced an objective response rate of 43% in patients with HER2-positive... Read More
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
“We continue to be very encouraged by the tolerability and antitumor activity of margetuximab with an anti-PD-1 mAb, an investigational, chemotherapy-free approach... Read More
Biotech Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
An early stage drug tested in a new study shows promising results for gastric cancer patients.
ENA NEWS: Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
New research published in European Cancer finds gastric cancer patients respond well to a new anti-HER2 drug, which binds to two distinct... Read More
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
New research presented at the American Society of Clinical Oncology annual conference this month shares the comprehensive research program is underway to... Read More